Clinical trial HOVON 150 AML/ AMLSG 29-18
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy (HOVON 150 AML/ AMLSG 29-18)
| Cancers | |
|---|---|
| Organ | Acute leukemia |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Oui |
| Sponsor | Hovon |
| EudraCT Identifier | 2018-000451-41 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03839771 |
| Inclusion criteria | IDH1 or IDH2 +, fit for standard chemotherapy |
| Last update |